ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Other Events
Item 8.01
On September 23, 2019, ADMA Biologics, Inc. (the “Company”) issued a press release announcing that Adam Grossman, the Company’s President and Chief Executive Officer, and Brian Lenz, the Company’s Executive Vice President and Chief Financial Officer, are scheduled to present a corporate overview at the 2019 Cantor Global Healthcare Conference in New York City, on Wednesday, October 2, 2019 at 10:40 AM ET.
The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
(d) Exhibits
| 99.1 | ADMA Biologics, Inc. Press Release, dated September 23, 2019. |
ADMA BIOLOGICS, INC. Exhibit
EX-99.1 2 e618665_ex99-1.htm Exhibit 99.1 ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference RAMSEY,…
To view the full exhibit click here
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.